Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled study of ST-0529 in moderate to severe active ulcerative colitis
MOH_2019-09-05_007344Phase 2Completed
- Sponsor
- Sublimity Therapeutics
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of STI-0529 in autoimmune colitis (4 arms), sponsored by Sublimity Therapeutics. Started Aug 2019; status: completed.
02
Drugs
STI-0529
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2019-09-05_007344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-09-05_007344.